Abstract
Mezlocillin is a new semisynthetic penicillin that inhibited 71% of the isolates of Serratia marcescens, 67% of Escherichia coli, 50% of Enterobacter spp., and 49% of Klebsiella spp. at a concentration of 12.5 μg/ml. It is also active against both indole-positive and -negative Proteus spp. and gram-positive cocci, except penicillin G-resistant Staphylococcus aureus. At a concentration of 100 μg/ml, it inhibited 94% of the isolates of Pseudomonas aeruginosa. It is more active than ampicillin, carbenicillin, and cephalothin against some gram-negative bacilli.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bodey G. P., Middleman E., Umsawadi T., Rodriguez V. Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer. 1972 Jun;29(6):1697–1701. doi: 10.1002/1097-0142(197206)29:6<1697::aid-cncr2820290638>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
- Bodey G. P., Stewart D. In vitro studies of semisynthetic alpha-(substituted-ureido) penicillins. Appl Microbiol. 1971 Apr;21(4):710–717. doi: 10.1128/am.21.4.710-717.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eickhoff T. C. Infectious complications in renal transplant recipients. Transplant Proc. 1973 Sep;5(3):1233–1238. [PubMed] [Google Scholar]
- Inagaki J., Rodriguez V., Bodey G. P. Proceedings: Causes of death in cancer patients. Cancer. 1974 Feb;33(2):568–573. doi: 10.1002/1097-0142(197402)33:2<568::aid-cncr2820330236>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]